Holen Sie sich die Stockscreener-App
1.15
2.54%
-0.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.18
Offen:
$1.17
24-Stunden-Volumen:
3.56M
Relative Volume:
1.85
Marktkapitalisierung:
$210.81M
Einnahmen:
$137.74M
Nettoeinkommen (Verlust:
$-27.97M
KGV:
-7.1875
EPS:
-0.16
Netto-Cashflow:
$-9.61M
1W Leistung:
-3.36%
1M Leistung:
-12.88%
6M Leistung:
-50.22%
1J Leistung:
-35.39%
1-Tages-Spanne:
$1.07
$1.19
1-Wochen-Bereich:
$1.07
$1.28
52-Wochen-Spanne:
$1.04
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
Firmenname
Heron Therapeutics Inc
Sektor
Branche
Telefon
(858) 251-4400
Adresse
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Vergleichen Sie HRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.15 | 216.31M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.74 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.23 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.92 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.63 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.82 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-04-23 | Eingeleitet | CapitalOne | Overweight |
| 2024-03-13 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Buy |
| 2020-02-20 | Bestätigt | Needham | Buy |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-04-05 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2018-03-01 | Bestätigt | Needham | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Outperform |
| 2017-09-27 | Eingeleitet | Northland Capital | Outperform |
| 2017-02-27 | Eingeleitet | Needham | Buy |
| 2016-10-26 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-06 | Fortgesetzt | Lake Street | Buy |
| 2016-05-03 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-10 | Eingeleitet | Lake Street | Buy |
| 2015-09-23 | Bestätigt | Leerink Partners | Outperform |
| 2015-09-02 | Eingeleitet | BofA/Merrill | Buy |
| 2015-08-03 | Bestätigt | Brean Capital | Buy |
| 2015-06-30 | Bestätigt | JMP Securities | Mkt Outperform |
| 2015-06-19 | Bestätigt | Leerink Partners | Outperform |
| 2014-08-07 | Eingeleitet | Noble Financial | Buy |
Alle ansehen
Heron Therapeutics Inc Aktie (HRTX) Neueste Nachrichten
Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Sentiment analysis tools applied to Heron Therapeutics Inc.2025 Price Momentum & Fast Momentum Entry Tips - newser.com
Heron Therapeutics Inc. Q3 Loss Increases, Misses Estimates - Nasdaq
Heron Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Heron Therapeutics Q3 2025 Financial Results - TradingView
HERON THERAPEUTICS, INC. /DE/ SEC 10-Q Report - TradingView
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress - GlobeNewswire
Heron Therapeutics Inc. stock daily chart insightsJuly 2025 Levels & Proven Capital Preservation Tips - newser.com
Ranking Heron Therapeutics Inc. among high performing stocks via toolsM&A Rumor & Growth Oriented Trade Recommendations - newser.com
Will Heron Therapeutics Inc. stock benefit from automation2025 EndofYear Setup & Community Consensus Stock Picks - newser.com
Why Heron Therapeutics Inc. (AXD2) stock could rally stronglyStop Loss & High Accuracy Swing Entry Alerts - newser.com
Can Heron Therapeutics Inc. stock weather global recessionShare Buyback & Safe Entry Point Alerts - newser.com
Heron Therapeutics Inc. stock chart pattern explainedEarnings Risk Summary & Reliable Price Breakout Signals - newser.com
Can Heron Therapeutics Inc. (AXD2) stock deliver consistent EPS growthMarket Performance Report & AI Powered Market Entry Strategies - newser.com
What analyst consensus says on Heron Therapeutics Inc. stockJuly 2025 Market Mood & Accurate Intraday Trade Tips - newser.com
Can trapped investors hope for a rebound in Heron Therapeutics Inc.2025 Biggest Moves & Daily Risk Controlled Trade Plans - newser.com
Can Heron Therapeutics Inc. recover in the next quarterPrice Action & Precise Entry and Exit Recommendations - newser.com
Heron Therapeutics Inc. stock prediction for this week2025 Historical Comparison & Consistent Growth Stock Picks - newser.com
Will Heron Therapeutics Inc. stock attract more institutional investorsInsider Selling & Reliable Breakout Forecasts - newser.com
Tools to monitor Heron Therapeutics Inc. recovery probabilityWeekly Gains Report & Risk Controlled Swing Alerts - newser.com
Should you wait for a breakout in Heron Therapeutics Inc.Portfolio Return Report & Entry and Exit Point Strategies - newser.com
Developing predictive dashboards with Heron Therapeutics Inc. data2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
Is Heron Therapeutics Inc. (AXD2) stock inflation resilient2025 Top Gainers & Reliable Volume Spike Trade Alerts - newser.com
What MACD and RSI say about Heron Therapeutics Inc.Weekly Trade Report & Free Safe Capital Growth Stock Tips - newser.com
Detecting price anomalies in Heron Therapeutics Inc. with AI2025 Market WrapUp & Safe Entry Point Identification - newser.com
Will Heron Therapeutics Inc. stock outperform Nasdaq indexTrade Entry Report & Fast Moving Trade Plans - newser.com
Why Heron Therapeutics Inc. (AXD2) stock attracts wealthy investorsJobs Report & Growth Oriented Trading Recommendations - newser.com
Finanzdaten der Heron Therapeutics Inc-Aktie (HRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Heron Therapeutics Inc-Aktie (HRTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
1.71%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):